期刊文献+

黄芪注射液联合刺五加注射液治疗冠心病心绞痛疗效观察 被引量:1

The Observation of Efficacy of Huangqi Injection in Combination with Ciwujia Injection in the Treatment of Coronary Heart Disease Angina Pectoris.
下载PDF
导出
摘要 目的:联合应用黄芪注射液和刺五加注射液治疗冠心病心绞痛,观察疗效及不良反应。方法:对100例冠心病心绞痛病人随机分成两组,对照组给予常规应用硝酸酯类、β受体阻滞剂、钙离子拮抗剂、肠溶阿斯匹林和极化液等治疗,治疗组在常规治疗的基础上给予黄芪注射液20mL+5%GS250mL和刺五加注射液40mL+5%GS250mL分步静滴,每日1次,疗程2周,观察两组患者用药前后心绞痛、心电图、血流变改变情况及不良反应。结果:治疗组心绞痛、心电图及血流变改变情况较对照组显著(分别为P<0.01,P<0.05,P<0.01),总有效率治疗组为94%,与对照组(56%)比较有显著差异(P<0.01),未见副反应。结论:黄芪注射液联合刺五加注射液治疗冠心病心绞痛疗效显著,无不良反应。 Objective: To investigate the effect of Huangqi injection in combination with Ciwujia injection in the treatment of coronary heart disease(CHD) angina pectoris.Methods: 100 patients with angina pectoris were randomly divided into two groups.The control group were outinely treated with Nitroglycerin,β-blocker,calcium channel blocker (CCB) , Aspirin,polariz liquid. On the base of normal treatment, the treatment group was injected with Huangqi 20mL+ 5%GS250mL 1/d and Ciwujia 40mL + 5%GS250mL 1/ d for two weeks. The changs of angina pectoris, electrocardiogram(ECG) , blovel change and adverse reaction of the drug were observed before and after treatment.Result:The treatment group in angina pectoris, ECG and blovel change had better effects than the control group( P<0.01,P<0.05,P<0.01 respectively) . The total effective rate of treatment group was 94% , compared with the control group (56%).There was significant difference (P<0.01).No side effects were observed. Conclusion:Huangqi injection in combination with Ciwujia injection are effective in the treatment of CHD angina pectoris. No adverse reaction were found.
出处 《医学理论与实践》 2003年第4期376-377,共2页 The Journal of Medical Theory and Practice
关键词 冠心病 心绞痛 黄芪注射液 刺五加注射液 疗效 不良反应 Coronary heart disease angina pectoris, Huangqi injection, Ciwujia injection
  • 相关文献

参考文献3

二级参考文献7

  • 1Luc G, Bard J M, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis, 2001,163(2):377-384.
  • 2Seman L G, Deluca C, Jenner J L,et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem, 1999,45(7):1039-1046.
  • 3Lundstam U, Herlitz J, Karlsson T, et al. Serum lipids, lipoprtein (a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med, 2002,251(2):111-118.
  • 4Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein (a) and coronary heart disease risk. Curr Cardiol Rep,1999,1(2):105-111.
  • 5Angles C E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res,1997,30(11):1271-1280.
  • 6Maeda S, Abe A, Seishima M, et al. Transient change of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989,78(1):145-150.
  • 7Greory Y H, Gordon D L. Fibrin D-dimer: A useful marker of thrombogenesis? Clini Sci,1995(89):205-214.

共引文献251

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部